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Autoiogous bone marrow transplantation (BMT) ~ is being evaluated at several 
medical centers as an alternative approach to aliogeneic BMT for the treatment 
of acute lymphoblastic leukemia (ALL) patients who do not have matched sibling 
donors (1,  2).  A  major limitation of autologous BMT is the  likely presence of 
residual  leukemia  in  the  remission  marrow  (2).  This  difficulty  makes  ex  vivo 
purging of autologous stem cell grafts before transplantation essential for ther- 
apeutic efficacy (3). Current ex vivo purging strategies involve the treatment of 
autologous marrow with cyclophosphamide congeners (3-5), mAb plus comple- 
ment (6-9), and immunotoxins (IT) (10-18). Our laboratory is committed to the 
evaluation of the clinical potential of IT in autoiogous BMT for ALL. We have 
begun  a  phase  I  trial  in  T-ALL using  intact ricin  IT as purgative reagents  to 
eliminate occult leukemic T-lineage blasts from autologous marrow grafts prior 
to reinfusion  (18).  In  common  B-lineage ALL,  our  Bone  Marrow  Transplant 
Team  at  the  University  of  Minnesota  has  emphasized  the  use  of mAb  plus 
complement  for  ex  vivo  bone  marrow  treatment  (19).  Despite  such  ex  vivo 
manipulation  of autologous  stem  cell grafts,  recurrent  leukemia  in  autotrans- 
planted patients remains tile major cause for treatment failure in ALL (19-21). 
Available methods do not determine whether relapses occur because of incom- 
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plete  purging  of marrow  or  incomplete  eradication  of leukemia  in  patients. 
Present clinical  trials usually rely on preclinical studies in which the efficacy of 
purgative reagents is evaluated against in vitro established tumor cell lines (7, 9). 
However, there is a marked heterogeneity in surface antigen expression among 
leukemia cell populations (22, 23) and neither the phenotype nor drug or toxin 
sensitivity of leukemic progenitor cells is as yet known. Therefore, model systems 
such as clonogenic assays of homogeneous leukemic cell lines, while potentially 
useful for quantitating  the  relative  effectiveness of various purgative  reagents 
and  optimizing  treatment  conditions,  cannot  be extrapolated  for clinical  ALL 
with any certainty.  We (14-17,  24, 25) and others (7, 9,  10, 26) have discussed 
the problems inherent  in using established ceil lines in vitro as a  model system 
for evaluating the antileukemic efficacy of a  purging  reagent.  These problems 
have received little attention because of the difficulty in growing freshly obtained 
ALL cells in vitro (26, 27). To our knowledge, none of the reagents currently 
under clinical evaluation have been tested directly against clonogenic blasts from 
ALL  patients,  and  therefore  there  is  no  evidence  that  they  can  effectively 
eliminate leukemic progenitor cells. In the absence of such data, it is difficult to 
determine the value of ex vivo marrow purging.  Clearly, the critical evaluation 
of purging  methods  at  the  level  of  leukemic  progenitor  cells  will  be  most 
important to determining whether the therapeutic outcome of autologous BMT 
in  ALL  can  be  improved  by  modifications  in  the  current  clinical  purging 
protocols. 
Herein, we report the results of a preclinical study examining the efficacy of 
B43-PAP,  a human  B  cell-directed  IT  containing  pokeweed antivirai  protein 
(PAP), against  leukemic progenitor cells from patients  with common B-lineage 
ALL. We show that  B43-PAP selectively eliminated blast progenitor cells in all 
10 patients,  with minimal  toxicity to normal progenitor cells. These studies are 
of special interest because, to our knowledge,  B43-PAP is the first mAb-toxin 
conjugate  to  prove effective against  common  B-lineage  ALL  blasts and  their 
progenitors. 
The leukemic progenitor cell assay described in this paper is devised to provide 
a  basis for future comparative studies of different purging  strategies,  with the 
aim  of defining  an  optimal  and  standardized  protocol  for  removing  residual 
clonogenic leukemia cells from autologous marrow grafts in common B-lineage 
ALL. Our investigation represents the first application of this novel colony assay 
to a major unresolved problem in human BMT for ALL. 
Materials and Methods, 
Patient Material.  12  patients  with  ALL  were  included  in  this  study.  Clinical and 
diagnostic data are summarized  in Table I. Bone marrow aspirate samples were procured 
by conventional  methods. Morphological classification was performed on Wright-Giemsa- 
stained slides using a modification  of the original  FAB classification (28). Blast cells were 
isolated by a single centrifugation on FicolI-Hypaque (1.077  g/cm3). Marker analyses by 
indirect immunofluorescence and flow cytometry were performed using a panel of mAb 
that define B-lineage (i.e., B43, BA-1, BA-2, BA-3) and T-lineage  (i.e., 35.1, T101, 3A- 
1) leukocyte differentiation antigens.  FITC-labeled goat F(ab')~ anti-mouse IgG (Cappel 
Laboratories, Cochranville,  NC) served as secondary antibody. Surface immunogiobulin 
(slg) was assayed by direct immunofluorescence using FITC-conjugated goat F(ab')2 anti- 
human  total  Ig (Kallestad,  Austin,  TX).  Background fluorescence was determined  by UCKUN ET  AL. 
TABLE  ] 
Clinical and Diagnostic Data on Patients with ALL 
349 
Diagnosis  New case or  Bone  marrow 
Patient  Sex  Age (yr)  (FAB)  relapse  (% blasts) 
1  M  18  L1  New  97 
2  M  3  L2  New  99 
3  F  5  LI  Relapse  94 
4  M  9  L1  Relapse  91 
5  F  !  LI  New  91 
6  F  12  L1  Relapse  91 
7  M  2  L1  Relapse  100 
8  F  2  L1  New  100 
9  F  2  L2  New  79 
10  F  2  L1  New  78 
ll  F  4  L1  New  100 
12  M  5  L1  New  95 
incubating  cells  with  an  IgG2a  murine  myeloma protein  (UPC  10;  Litton  Bionetics, 
Charleston,  SC). Cells  were  analyzed  for  immunofluorescence  using  a  Spectrum  III 
Cytofluorograph (Ortho Diagnostics,  Raritan,  N  J).  We attempted to examine only the 
lymphoblasts within each specimen by appropriate gating. Samples were scored as positive 
when >20% of cells bound the antibody used. 
Colony Assay  for Common B-lineage ALL Progenitor Cells.  Freshly obtained bone marrow 
blasts  were suspended  in  a-MEM  supplemented  with  0.9%  methylcellulose,  15%  FCS, 
15%  platelet-rich  fresh  human plasma,  10%  PHA-LCM (PHA-stimulated lymphocyte- 
conditioned medium), 1% MEM vitamin solution, 0.5% MEM amino acids solution, 0.5% 
MEM  nonessential amino acid solution, 2 mM L-glutamine,  1 mM sodium pyruvate, 50 
#M  2-ME,  4  #g/ml  D-L-serine, and  4  #g/ml  asparagine.  PHA-LCM was  prepared  by 
culturing  107  peripheral  blood  mononuclear  cells  per  milliliter  from  a  patient  with 
polycythemia vera for 4 d at 37°C in  5% CO2 in a-MEM containing 1% (vol/vol) PHA 
(HA 15; Wellcome Diagnostics,  Dartford, United Kingdom) and  1% human albumin (10 
GM; Sigma Chemical Co., St.  Louis, MO).  All batches of PHA-LCM, FCS, and human 
plasma were titrated to determine the optimal concentrations, and kept frozen at -20°C 
until use. Blast colony formation in our assay system required the presence of PHA-LCM. 
A  single  batch of PHA-LCM was  used  throughout this  study,  since  data on different 
patients can be compared only under standardized assay conditions. This particular batch 
of PHA-LCM was  prepared  by  stimulating  peripheral  blood  mononuclear cells  of a 
polycythemia vera patient with PHA. However, other batches of PHA-LCM, prepared by 
using peripheral blood lymphocytes  of healthy volunteer donors as well as the supernatants 
of activated helper T cell clones derived from normal individuals are also able to promote 
in vitro B-lineage  blast colony formation. We strongly believe that pluripotent colony- 
stimulating factor (CSF) and/or IL-3 in these conditioned media support colony formation 
by leukemic progenitor cells in common B-lineage ALL. Three of five PHA-LCM batches 
obtained from different donors promoted blast colony formation, whereas only 3 of 17 
plasma batches and two of three FCS batches yielded successful cultures (data not shown). 
Hence,  the  reproducibility of blast  colony formation requires  a  careful and  thorough 
screening of the PHA-LCM, plasma, and FCS batches. The ill-defined  stimulatory activity 
present in the plasma of some individuals appears to be essential  for the development of 
leukemic B-lineage blast  colonies. Duplicate  1 ml samples were cultured in 35 mm Petri 
dishes for 7 d at 37°C in a humidified 5% CO2 atmosphere. On day 7, colonies containing 
>20 cells were counted using an inverted phase microscope with high optical resolution. 
Subsequently,  all  colonies  were  pooled  for  further  cytochemical and  immunological 
analysis of colony blasts.  In the experiments described in this paper, we started cultures 
with  105 bone marrow mononuclear cells (BMMNC)/ml. In some experiments,  104 cells 350  IMMUNOTOXIN  ELIMINATION OF  LEUKEMIC  B-LINEAGE PROGENITORS 
from pooled colonies were replated under the initial culture conditions to measure the 
self-renewal ability of blast progenitors. 
Cytochemical and Immunological Analysis of Colony Blasts.  Cells from pooled colonies 
were deposited  on  slides by cytocentrifugation.  The  morphology of lymphoblasts was 
studied in Wright-Giemsa-stained cytospin preparations. In cytochemical studies, lympho- 
blasts were evaluated for staining by periodic acid-Schiff (PAS) by the McManus method 
(29),  and  for nonspecific esterase (NSE) activity using a-naphthyl acetate as substrate. 
Sudan Black B and myeloperoxidase stains were also used to detect contaminating normal 
myelomonocytic cells. For surface marker analyses by indirect immunofluorescence, slides 
were fixed in acetone (10 min), dried, and 100 ~1 mAb was added directly on top of cells. 
mAb were used in antibody excess. After 30 min incubation at room temperature in a 
humidity chamber, cells were washed twice in PBS to remove unbound antibody. FITC- 
conjugated goat F(ab')~ anti-mouse IgG (Cappel Laboratories) was used as second anti- 
body (incubation for 30 min, then washed three times in PBS).  For background fluores- 
cence, an IgG2a murine myeloma protein (UPC 10; Litton Bionetics) was substituted for 
mAb.  The  percentage  of cells  expressing  each  marker was  determined  using  a  Zeiss 
fluorescent  microscope equipped  with  Ploem  epi-illumination.  Quantitative  data  were 
obtained from examination of 100-200 cells. The marker profiles were analyzed using a 
panel of murine mAb that define lymphoid and myeloid/erythroid (M/E) differentiation 
antigens.  Specifically, we used the following mAb. T  cell  panel:  35.1,  anti-CD2(T,p50) 
(30);  T101, anti-CD5(T,p67) (31);  3A1, anti-CD7(T,p41) (32).  B cell panel: BA-2, anti- 
CD9(nT-nB,p24) (33);  BA-3, anti-CD10(nT-nB,pl00) (34);  B43, pan-B (14);  BA-1, anti- 
CD24(B,G,p45,55,65)  (35).  M/E panel: anti-MY8 (36);  2 RIO, anti-glycophorin A (37). 
Serological  cluster  designations  were  assigned  at  the  First  (Paris,  1982)  and  Second 
(Boston,  1984) International Workshops on Human Leukocyte Differentiation Antigens. 
Immunotoxin Synthesis.  PAP is a single-chain polypeptide toxin (Mr 29,000) that cata- 
lytically inactivates the 60 S subunit of eukaryotic ribosomes, and was isolated from spring 
leaves of pokeweed (Phytolacca americana) as previously described (38).  mAb B43 (IgG1, 
pan-B) (14),  3A1  (IgG1, pan-T, anti-CD7) (32), and T101  (IgG2a, pan-T, anti-CD5) (31) 
were linked to PAP by a disulfide bond using N-succinimidyl-3-(2-pyridyldithio)propionate 
(SPDP), as previously described (39). Pan-T IT were purified on a Sephacryl S-200 column 
(1  ×  150 cm). Pan-B IT B43-PAP was purified by adsorbtion on protein A-Sepharose as 
described earlier (14). No free PAP was detected on PAGE under nonreducing conditions. 
Free antibody contamination was estimated to be <20% by gel electrophoresis. The molar 
PAP/IgG  ratio  in  the  conjugates  was  estimated  by a  specific homologous  RIA  using 
radioiodinated PAP (39, 40). By competitive inhibition of ~25I-PAP binding to rabbit anti- 
PAP antibodies by PAP and PAP containing IT, this ratio was found to be 2:1  in B43- 
PAP,  1:1  in  3A1-PAP,  and  1:1  in  T101-PAP.  IT were evaluated  for their  ability to 
inactivate protein synthesis in a cell-free translation system using rat liver ribosomes and 
polyuridylic acid as message, according to the method previously described (39, 41). All 
three  IT were found to be equally potent inhibitors of polyuridylic acid translation at 
equimolar concentrations (data not shown). We have used an average molecular weight 
of 180,000  (3A1-PAP, T101-PAP) or 210,000 (B43-PAP) for IT to calculate the molar 
concentrations applied in this study. 
B43  mAb reacts with  most of B  cells isolated from peripheral blood and  lymphoid 
organs, EBV-transformed B lymphoblastoid, Burkitt's lymphoma, B-ALL and pre-B-ALL 
cell lines.  The majority of patients with B cell lymphoma, chronic lymphocytic leukemia 
(CLL), B-ALL, common B-lineage ALL, hairy cell leukemia express the surface determi- 
nant recognized by B43  mAb. In contrast, patients witb AML, T-cell ALL, or T  cell- 
derived non-Hodgkin's lymphoma show no reactivity with B43. This mAb does not bind 
to committed myelomonocytic (CFU-GM; colony-forming units/granulocytes and macro- 
phages), erythroid (CFU-E), megakaryocytoid (CFU-MK) precursors, granulocytes, eryth- 
rocytes, platelets,  T-lymphocytes, or plasma cells.  The detailed  information about the 
reactivity pattern of B43  will be published in a  separate report. (Uckun,  manuscript in 
preparation). 
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sandwich method in which we incubated the cells in a sequential fashion with (a) IT (4 x 
10 -8 M, 30 rain, 4°C), (b) affinity-purified rabbit anti-PAP antiserum (50 #g/ml,  15 min, 
4°C), and (c) FITC-conjugated goat anti-rabbit IgG (Miles Laboratories, Elkhardt,  IN) 
(1:50 dilution,  15 min, 4 ° C) as previously described (14). Cells were analyzed by cytoflu- 
orometry using a FACS IV (Becton Dickinson Immunocytochemistry Systems, Mountain 
View, CA).  Fluorescence profiles were plotted with the aid of an Apple II computer as 
histograms of relative intensity over 256 channels vs.  number of cells in  each channel 
(17). Background fluorescence staining was obtained by incubating cells with an equimolar 
mixture of free mAb (B43,  3A1, TI01; 4  x  I0  -8 M each) and unconjugated PAP (8 x 
10 -8 M) instead of PAP-IT. 
Treatment of Cells with IT.  107 cells/ml were treated with IT for 8 h (standard protocol) 
or 4 h (short incubation protocol) at 37°C in 5% CO2 in RPMI 1640 plus 20% (vol/vol) 
FCS. After treatment, cells were washed twice in RPMI  1640  plus 5% (vol/vol) FCS to 
remove unbound IT. 
Evaluation of B43-PAP-induced Inhibition  of Protein  Synthesis in Common B-lineage ALL 
Cells.  The extent of protein synthesis inactivation was determined as percent inhibition 
of protein  synthesis --  100  -  100  x  ([3H]leucine incorporation  [cpm] per  105 treated 
cells)/([3H]leucine  incorporation  [cpm]  per  105  untreated  cells).  The  incorporation  of 
[3H]leucine into cellular protein was determined as previously described (14).  Controls 
were  (a)  untreated  samples, (b) samples treated  with  two control  IT directed  against 
T-lineage associated surface determinants  (i,e.,  3A1-PAP and T101-PAP),  (c) samples 
treated with a mixture of free B43 mAb and unconjugated PAP, and (d) samples of two 
different nontarget leukemic T  cell lines that are sensitive to PAP (i.e., HSB-2 and MOLT 
4). 
Evaluation  of Cytotoxicity of B43-PAP Against  Common B-lineage  ALL Progenitor  Cells. 
Following B43-PAP  treatment,  the  survival of leukemic progenitor cells was measured 
using  the  colony assay  described  above.  The  extent  of cytotoxicity was  expressed as 
percent inhibition of leukemic progenitor cells and was calculated as 100 -  100 x  (mean 
number of blast colonies per  105 treated cells)/(mean number of blast colonies per  105 
untreated cells).  In these experiments, we included the following controls: (a) untreated 
samples, (b) samples treated with  two control  IT directed against T-lineage-associated 
surface  determinants  (i.e.,  3A1-PAP  and  T101-PAP),  and  (c)  samples treated  with  a 
mixture of free B43  mAb and unconjugated  PAP. The nonspecific cytotoxicity of B43- 
PAP  against  normal  bone  marrow progenitor  cells  was evaluated  in  stem  cell  colony 
assays. 
Stem Cell Colony Assays.  Toxicity of B43-PAP treatment (8 h at 37 °C) against normal 
monopotent (CFU-GM, CFU-E, CFU-MK) and pluripotent (CFU-GEMM) bone marrow 
progenitor cells was evaluated by colony assays. The detailed methodology of this colony 
assay system has  been  described  elsewhere  (25,  42).  Data  were  expressed as  percent 
control colony formation as 100 X (mean number of colonies per 10  s treated cells)/(mean 
number of colonies per 105 untreated cells). 
Results 
Immunological  Marker  Profiles  of  Common  B-lineage  ALL  Cells.  12  pa- 
tients  with  ALL  were  studied.  The  immunological  profiles  of  the  patients' 
BMMNC  are shown in Table II. No patient expressed the T-lineage associated 
markers  CD2(T,pS0),  CD5(T,p67),  or  CD7(T,p41).  In  contrast,  the  cells 
from  all  the  patients  reacted  with  BA-3,  an  mAb  directed  against  CD10 
(nT-nB,pl00)/CALLA  surface determinant.  There  was a  marked variability in 
the number of BA-3 + bone marrow blasts among the patient population ranging 
from 33% (patient 5) to 98% (patient 11) (median, 80.5%). All patients expressed 
the  B-lineage-associated antigens  CD9 and  CD24  but  lacked sIg.  Importantly, 
the marrow blasts from all the patients expressed the B-lineage-associated surface 
determinant  recognized  by  the  B43  mAb.  B43  was  conjugated  to  the  plant 352  1MMUNOTOXIN  ELIMINATION  OF  LEUKEMIC  B-LINEAGE  PROGENITORS 
TABLE  II 
Immunological Marker Profiles of Patients" Bone Marrow Blasts 
Patient 
Cells (%) reactive with 
T-lineage markers  Cells (%) reactive with B-lineage markers 
CD2  CD5  CD7  CD9  CD10  CD24  B43  slg  35.1  T101  3AI  BA-2  BA-3  BA-1 
1  4  4  3  92  59  87  88  4 
2  13  9  5  83  94  77  88  11 
3  5  4  3  85  79  87  42  3 
4  1  1  0  72  87  91  95  1 
5  3  3  3  75  33  76  91  7 
6  7  3  3  94  94  83  95  5 
7  I  1  1  96  61  94  90  3 
8  2  2  2  90  73  87  41  5 
9  11  12  10  75  78  74  85  14 
10  5  4  4  72  95  85  96  2 
11  2  2  2  34  98  79  98  4 
12  8  5  10  39  82  83  86  7 
Numbers represent percentage of cells reactive with the given antibodies directed against T- and B- 
lineage surface determinants. Marker analyses by  immunofluorescence and  flow cytometry were 
performed as described in Materials and Methods. sIg, surface Ig, 
TAaLE  III 
Immunotoxin Binding and Immunotoxin-induced Inhibition of Protein Synthesis in 
Common B-lineage ALL Cells 
Cells stained* for PAP (%)  Percent inhibition of protein synthesis* 
Pa-  B43-PAP  3A 1-  TI 01-  B43-mAb 
tient  B43-  3A1-  T10I-  PAP  PAP  +  PAP 
PAP  PAP  PAP  8-h treat-  4-h treat-  8-h treat-  8-h treat-  8-h treat- 
ment  ment  ment  ment  ment 
1  89.5  6.2  NT  99.5  98.2  6.5  NT  0.0 
2  77.8  1.3  NT  91.5  89.7  0.0  NT  0.0 
3  85.8  11.1  NT  99.6  95.6  9.2  NT  0.0 
4  91.6  3.9  5.9  97.3  NT  2.5  NT  0,0 
5  77.1  5.4  5.3  95.5  NT  0.0  28.9  NT 
6  83.4  NT  8.6  95.4  NT  NT  0.0  2.4 
7  96.0  2.7  3.6  98.7  NT  NT  32.4  0,0 
8  89.4  NT  10.3  97.7  NT  NT  0.0  0,0 
9  83.8  NT  7.7  NT  89.3  NT  27.9  0.0 
10  90.2  NT  9.4  NT  98.8  NT  16,6  4.7 
11  79.5  NT  4.6  NT  99.4  NT  4,9  0.0 
12  86.8  NT  NT  NT  98.4  NT  NT  0.0 
* The  binding of PAP  IT  to  leukemic  blasts was  determined by  a  double  sandwich method as 
described in  Materials and Methods. Cells were analyzed by cytofluorometry using a  FACS IV, 
Results were expressed as the percentage of cells stained for PAP. NT, not tested. 
* 107 cells/ml were incubated with IT (4 x  10 -s M) or unconjugated antibody (4 x  10  -8 M) and PAP 
(8  X  10 -s M) mixtures at  37°C for the indicated treatment periods. After treatment, cells were 
washed to remove unbound IT and cultured at 37°C in 5% CO~ atmosphere. The incorporation 
of [3H]leucine into cellular protein was determined at 24 h posttreatment as described in Materials 
and Methods. Results were expressed as percent inhibition of protein synthesis =  100  -  100  x 
([~H]leucine incorporation [cpm]/105 treated cells)/([SH]leucine incorporation [cpm]/10  ~ untreated 
cells). UCKUN  ET  AL.  353 
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FIGURE  1.  Binding  of B43-PAP  to  common  B-lineage  ALL  cells.  Leukemic  blasts  were 
analyzed by indirect immunofluorescence and cytofluorometry using a FACS IV. Fluorescence 
profiles were plotted as histograms of relative fluorescence intensity over 256 channels vs. cell 
number in each channel. Background fluorescence (Control) was obtained using a  mixture of 
free mAb and unconjugated PAP. T101 -PAP and 3AI -PAP were used as control IT. 
hemitoxin  PAP in the present studies to generate an IT reactive with common 
B-lineage ALL cells. 
Binding of B43-PAP IT to Common B-lineage ALL Cells.  Bone marrow  blasts 
from patients were examined for the presence of bound IT after treatment with 
4 ×  10 -8 M PAP IT. As shown in Table III, common B-lineage ALL cells reacted 
with the B43-PAP IT in all  12 cases studied.  The number of B43-PAP-labeled 
cells ranged  from  77.1%  (patient  5) to 96.0%  (patient  7) (median,  86.3%).  In 
contrast,  these blasts did not bind control  IT 3A1-PAP and  T101-PAP,  which 
are directed against T-lineage-associated  surface determinants.  Representative 
FACS histograms from five patients are shown in Fig.  1. 
B43-PAP-induced Inhibition of Protein Synthesis in Common B-lineage ALL Cells. 
The  cell  type-specific cytotoxicity of B43-PAP was evaluated  by inhibition  of 
protein  synthesis  in  target  common  B-lineage  ALL cells.  Bone marrow  blasts 
(10  r celis/ml) from eight patients were treated with 4  x  10  -8 M B43-PAP for 8 
h at 37°C. This treatment protocol produced 91.5% (in patient 2) to 99.6% (in 
patient 3) inhibition of protein synthesis in target B-lineage leukemic cells (Table 354  IMMUNOTOXIN  ELIMINATION  OF  LEUKEMIC  B-LINEAGE  PROGENITORS 
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FIGURE  2.  Inhibition  of protein  synthesis in  common  B-lineage  ALL  cells  by  B43-PAP. 
Leukemic  blasts  were  incubated  in  triplicate  for  4  h  at  37°C  in  the  presence  of various 
concentrations of B43-PAP.  Percent control  [SH]leucine incorporation  in treated  cells as an 
index of residual ribosomal activity was determined as described in Materials and Methods. 
HSB-2 and MOLT  4 are PAP-sensitive leukemic T  cells that were used as nontarget controls. 
III). In contrast, 3A1-PAP (anti-CD7) elicited <10%  inhibition of protein syn- 
thesis in common B-lineage ALL cells at this IT concentration. By comparison, 
T 101-PAP (anti-CD5) inhibited a mean of 26.5% of protein synthesis in four of 
seven cases  (patients 5, 7, 9, and 10). The mean percentage of cells stained for 
bound T I01-PAP by indirect immunofluorescence was only 6.5  in these four 
patients (Table III). In additional controls, a  mixture of 4  ×  10  -8  M free B43 
mAb  and  8  ×  10  -s  M  unconjugated  PAP  did  not  inhibit  the  [SH]leucine 
incorporation by these B-lineage leukemic cells. 
We also examined the efficacy of 4  h  treatment with B43-PAP.  Significant 
inhibition was observed at 0.5 ×  10 -8 M B43-PAP, and at 4 X 10 -8 M, >90% of 
[SH]leucine incorporation was inactivated in common B-lineage ALL blasts (Fig. 
2). As shown in Table III, this short incubation protocol with 4 ×  10  -8 M B43- 
PAP induced substantial inhibition of protein synthesis in all 7 common B-lineage 
ALL cases.  The median inhibition of cellular protein synthesis was 98.2%.  At 
this conjugate concentration, B43- nontarget blasts from neoplastic T  cell lines 
(i.e., HSB-2 and MOLT-4) were not inhibited. We have previously reported that 
these T  cell lines are PAP sensitive and were inhibited at very low concentrations 
of T  cell directed PAP-IT (13, 43). These findings provide further evidence that 
the high antileukemic activity of B43-PAP  is cell type-specific and occurs via 
antibody binding. 
Colony-forming and Self-renewing Abilities of Common B-lineage ALL Progenitor 
Cells.  Freshly obtained bone marrow blasts from 12  common B-lineage ALL 
patients were assayed for primary colony formation in vitro. Successful cultures 
were obtained in 10 of 12 cases.  Paired daughter cells appeared in 8 of these 10 
cases within 24 h. In two cases (i.e., patients 2 and 4), there was a lag period of 
-48  h  until  the  first paired  blasts  were  observed.  After  72  h  of incubation, UCKUN ET  AL.  355 
FIGURE 3.  (A) Picture of part of a Petri dish containing compact clusters and colonies of B- 
lineage lymphoblasts cultured for 5 d (patient 3).  Note the differences in size. (× 5). (B) 
Photomicrograph of a day 7 blast colony  (patient 10). (x 19). (C) Photomicrograph of a day 7 
blast colony  (patient 5). (x 38). 
spherical clusters of 10-20 tightly associated cells were discernible in all successful 
cultures  (i.e.,  10  of  12  cases)  (Fig.  3A).  Colonies  containing  >20  blasts  were 
counted on day 7 (Fig.  3B). The blasts in these colonies were round and had a 
translucent  cytoplasm with  a  distinct  cell border of high  refractility  (Fig.  3, B 
and C). Colonies were compact and usually contained <200 cells. Therefore, we 
could  easily and  accurately  count  >2,000  distinct  colonies in  a  single  35-mm 
Petri dish. 
Blast colony formation  was linear  with  respect to numbers  of cultured  cells 
between  l0 s  and  105  leukemic  blasts  per  Petri  dish  (data  not  shown).  The 
apparent cloning frequency of blast progenitor cells in cultures started with  105 
leukemic blasts varied from 0.09% (i.e., 90 colonies per 105 BM blasts) to 2.63% 
(i.e., 2,630 colonies per  105 BM blasts). In the  10 cases with successful cultures, 
day 7 blast colonies displayed a marked variability in cell number, ranging from 
~20 cells to >200 cells per colony (Fig. 3, B and C). 
The self-renewal capability of blast progenitor cells was evaluated in replating 
experiments. Table IV compares the secondary plating efficiency of blasts pooled 
from primary colonies in three cases with the primary plating efficiency of bone 
marrow blasts. Too few surplus blasts were recovered from the primary colonies 
of other patients to test for their self-renewal ability. In all three cases, secondary 
colonies  appeared  earlier  than  the  primary  colonies  (within  72  h).  Colonies 
contained >50 cells and started to disperse on day 5. Petri dishes were harvested 
on day 7 for immunological marker analyses. Secondary plating efficiencies were 
higher than the primary plating efficiencies in all cases but did not exceed 7.12% 
(patient 7). 
Both  primary  and  secondary blast  colony formation  was  dependent  on  the 
copresence  of FCS,  human  plasma,  and  PHA-LCM  in  this  assay  system.  No 
colony formation  was obtained in control cultures  that  lacked one or more of 
these three supplements (data not shown). 
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TABLE  IV 
Primary and Secondary B-lineage Blast Colonies in Culture 
Patient 
Primary colony formation*  Secondary colony formation* 
Plating  Plating 
Colonies/104  effi-  Surface phe-  Colonies/104  effi-  Surface phe- 
BMMNC  ciency  notype (%)0  blasts  ciency  notype (%)0 
(%)  (%) 
197 (193,201)  1.97  97 BA-2  250 (241,259)  2.50  90 BA-2 
0 BA-3  0 BA-3 
98 B43  83 B43 
25 BA-1  38 BA-1 
133 (112,154)  1.33  90 BA-2  563 (540,586)  5.63  85 BA-2 
40 BA-3  55 BA-3 
90 B43  82 B43 
35 BA-1  50 BA-1 
250 (248,252)  2.50  99 BA-2  712 (699,725)  7.12  79 BA-2 
58 BA-3  50 BA-3 
85 B43  96 B43 
91  BA-1  83 BA-1 
* Duplicate samples of 104 freshly obtained bone marrow mononuclear cells were assayed for blast 
colony formation  in methylcellulose cultures as described in  Materials and  Methods.  On day 7, 
colonies containing >20  blasts  were counted  using an  inverted phase  microscope.  Results were 
expressed as the mean number of colonies per 104 BMMNC, and as the plating efficiency. Numbers 
in parentheses represent the actual number of colonies from individual dishes. 
~; Duplicate samples of 104 blasts  pooled from day  7  colonies were assayed  for secondary  colony 
formation  in  methylcellulose  cultures  as  described  in  Materials  and  Methods.  Cultures  were 
evaluated for colony formation as above. Results were expressed as the mean number Of secondary 
colonies per 104 blasts,  and as the plating efficiency. Numbers in parentheses represent the actual 
number of colonies from individual dishes. 
0 Surface phenotype analyses of colony blasts,  determined  by indirect immunofluorescence, were 
performed on acetone-fixed cytospin preparations as described in Materials and Methods. Numbers 
represent the percentage of~zolony blasts reactive with the mAb. 
Blasts.  The cells from pooled colonies showed >95% viability, as estimated by 
trypan blue exclusion. They had blast morphology with a basophilic cytoplasm, 
prominent vacuolation, irregular  nuclear membrane, and prominent nucleoli 
(Fig. 4). The colony blasts from different patients displayed marked differences 
with respect to size; nuclear/cytoplasmic ratio; basophilia of cytoplasm; nuclear 
membrane contour; nucleolar size, number, and prominence;  and amount and 
prominence of vacuolation (Fig.  4).  Cytochemical evaluation of colony blasts 
showed that they are Sudan black-negative, myeloperoxidase-negative, NSE-, 
and PAS  +.  The  PAS  + cells showed a  strong staining intensity. The stain  was 
irregularly distributed within the cytoplasm and occurred in clumps or coarse 
and fine  granules  (Fig.  4).  In  summary,  colony cells  had  morphologic and 
cytochemical features consistent with ALL. 
Blasts from pooled day 7 colonies displayed a marked heterogeneity in expres- 
FIGURE 4.  (A) Wright-Giemsa-stained cells pooled from day 7 blast colonies. Note the blast 
morphology with a basophilic cytoplasm, irregular nuclear membrane, prominent nucleoli and 
vacuolation. (B) Colony blasts were evaluated for staining by PAS. Note the strong staining 
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TABLE  V 
Immunological Marker Profiles of Cultured Cells Pooled  from Day 7 Blast Colonies 
Patient 
Cells (%) reactive with 
T-lineage markers 
Cells (%) reactive with B-lineage 
markers 
Ceils (%) 
reactive with 
myeloid/erythroid 
markers 
CD2  CD5  CD7  CD9  CD 10  CD24  anti-  anti-gly- 
B43  cophorin  35.1  TIO1  3A1  BA-2  BA-3  BA-I  MY 8 
A (R10) 
1  1  2  0  97  0  98  25  2  0 
2  0  NT  NT  95  67  94  92  0  NT 
3  2  0  0  90  40  90  35  1  NT 
4  1  NT  NT  65  84  55  34  0  NT 
5  0  NT  NT  85  0  66  40  0  NT 
6  0  NT  NT  98  78  95  93  0  0 
7  0  0  2  99  58  85  91  3  1 
8  0  NT  NT  86  66  75  90  NT  NT 
10  1  0  0  49  27  74  85  1  0 
11  0  NT  0  95  0  90  10  0  0 
Surface  marker  analyses  using  indirect  immunofluorescence were  performed on  acetone-fixed 
cytospin preparations. The number of cells expressing each marker was determined using a  Zeiss 
fluorescent microscope. Quantitative data were obtained from examination of 100-200 cells.  Num- 
bers  represent percentage of colony blasts reactive with  the  mAb.  NT,  not  tested.  No  colony 
formation of any type was noted among cells from patients 9 and 12. 
sion of B-lineage-associated surface determinants (Table V).  In  3  of 10 cases 
(patients 2, 6, and 7) the immunological phenotype of colony blasts was identical 
to that of the bulk blast population before culture, and in the remaining 7 cases 
it differed from the preculture evaluation. Two major immunological groups 
could be identified based on the reactivity pattern with BA-2 (anti-CD9), BA-3 
(anti-CDl0), BA-1  (anti-CD24), and B43  mAb. The first group was comprised 
of four cases (patients 2,  6-8).  Colony blasts in this group had BA-2  ÷, BA-3  ÷, 
BA-1 ÷, B43 ÷ marker profiles. Thus, their immunological phenotype was consist- 
ent with that of bone marrow lymphoblasts before culture.  In particular,  58- 
78% of cultured blasts expressed CD10/CALLA in this group (Table V). The 
second major group was comprised of three cases (patients 1, 5, and 11) in which 
the cells in the blast colonies did not express CD 10/CALLA. In this group, the 
expression of CD24 was also significantly greater on the uncultured initial blast 
population than on the cells pooled from day 7 blast colonies (Table V). In the 
remaining three cases (patients 3, 4, and 10), cultured blasts had marker profiles 
that differed from the evaluation before culture, as well as from the immunolog- 
ical phenotype observed in the two major groups described above. There was no 
apparent correlation between the expression of B-lineage-associated antigens on 
cultured blasts and the number or size of blast colonies. 
In all  10 cases with successful cultures, the colony blasts did not express T- 
lineage-associated antigens (i.e.,  CD2,  CD5,  and  CD7)  or  M/E  markers (i.e., 
MY8  and  glycophorin A)  but  were stained with  at  least  two  different mAb 
directed against distinct B-lineage-associated surface determinants (Table V). 
Despite considerable heterogeneity, the marker profiles detailed in Table V are 
consistent  with  B-lineage  ALL.  Importantly,  in  all  cases,  a  large  fraction  of UCKUN  ET  AL.  359 
TABLE VI 
Effect of lmmunotoxin Treatment on Common B-lineage ALL Progenitor Cells 
Mean number of blast  colonies per 10  s BMMNC  Inhibition (%) of blast progenitor cells 
Patient  No treat-  B43 mAb  B43-  B43-  3AI-  T10I-  B43 mAb  B43-  B43-  3A1-  TI01- 
+  PAP  PAP  PAP  PAP  PAP  + PAP  PAP  PAP  PAP  PAP 
ment  (8 h)  (8 h)  (4 h)  (8 h)  (8 h)  (8 h)  (8 h)  (4 h)  (8 b)  (8 h) 
1  1,830  1,925  0  0  1,710  NT  0.00  599.93  599.93  7.57  NT 
2  160  155  0  0  210  NT  3.13  ->99.38  ->99.38  0.00  NT 
3  1,150  983  0  0  1,001  NT  14.52  ->99.91  ->99.91  12.96  NT 
4  90  132  0  NT  I03  93  0.00  ->98,89  NT  O.0O  0.OO 
5  210  205  2.3  NT  253  213  2.38  98.81  NT  0.00  0.00 
6  197  163  0  NT  NT  208  17.26  ->99.49  NT  NT  0.00 
7  2,631  2,540  0  NT  2,701  2,230  3.46  ->99.95  NT  0.00  15.24 
8  113  125  9  NT  NT  102  O.O0  92..00  NT  NT  9.73 
10  514  502  NT  0  NT  487  2.33  NT  ->99.81  NT  5.25 
11  505  643  NT  0  NT  525  0.00  NT  ->99.80  NT  0.00 
After IT  treatment  (4  x  10-" M) at  37°C  for the  indicated  time periods,  the survival of leukemic  B-lineage progenitor 
cells was measured  in a  colony  assay system as described  in Materials and  Methods.  Results were expressed  as the mean 
number  of blast colonies per 105 BMMNC  obtained from treated and untreated  duplicate samples. The percent inhibition 
of blast progenitor cells was calculated as 100 -  (mean number  of blast colonies per 105 treated cells) x  100/(mean number 
of blast colonies per  105 untreated  cells). 
NT,  not tested.  No colony growth of any type was noted among cells from patients 9  and  12. 
cultured  blasts  in  day  7  colonies  expressed  the  B-lineage-associated  surface 
determinant  defined by B43 mAb, which has been used as a  carrier  transport 
protein for the plant hemitoxin PAP in our study. 
The immunological phenotype of cells pooled from secondary blast colonies 
was identical to that of blasts in the primary colonies (Table IV). 
B43-PAP-induced Inhibition of Common B-lineage ALL Progenitor Cells.  Given 
the  heterogeneity  in  antigen  expression  and  toxin  sensitivity among  leukemia 
cell populations, combined with the current lack of knowledge about the immu- 
nological profile or PAP sensitivity of clonogenic ALL blasts, measurements of 
[3H]leucine  incorporation  on  the  bulk  population  alone  might  not  permit  a 
precise determination  of the  frequency at  which  blast progenitor  cells escape 
killing. Therefore, it was important to evaluate the immunotherapeutic potential 
of B43-PAP in a  clonogenic assay system. Table VI shows the efficacy of B43- 
PAP against  leukemic bone  marrow  progenitor  cells from  common  B-lineage 
ALL patients.  No  blast  colonies were detected in  six  of eight  leukemic  bone 
marrow  samples  treated  with  4  x  10  -8  M  B43-PAP  for  8  h  at  37°C.  4  h 
incubation with B43-PAP proved as effective as 8 h incubation, and no residual 
blast colonies  were  detected  in  IT-treated  samples  from  any  of five  patients 
tested (Table VI).  In summary, colony formation was completely inhibited in 8 
of  10  cases  by  B43-PAP  (4-  or  8-h  incubations  at  37°C).  The  inhibition  of 
leukemic progenitor cells ranged from 92% (patient 8) to ___99.96% (patient 7), 
with a mean value of ->98.9%. In contrast to the toxicity of B43-PAP, a mixture 
of 4  x  10  -8 M free B43 mAb and 8 x  10  -8 M unconjugated PAP did not elicit 
a significant inhibition of blast progenitor cells. Control IT 3A 1-PAP and T 101- 
PAP only minimally affected the colony forming ability of common  B-lineage 
ALL progenitor cells (Table VI). 
Effect  of B43-PAP  on  Normal  Monopotent  (CFU-GM,  CFU-E,  CFU-MK)  and 
Pluripotent  (CFU-GEMM)  Bone  Marrow  Progenitor  Cells.  BMMNC  from  two 
healthy individuals were examined for B43-PAP reactivity by indirect immuno- 360  IMMUNOTOXIN  ELIMINATION  OF  LEUKEMIC  B-LINEAGE  PROGENITORS 
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FICURE 5.  Effects of B43-PAP on normal myelomonocytic (CFU-GM), erythroid (CFU-E), 
megakaryocytoid  (CFU-MK),  and  pluripotent  (CFU-GEMM)  progenitor  cells.  Normal 
BMMNC from two healthy donors were incubated in triplicate for 8 h at 37°C in the presence 
of various concentrations of B43-PAP.  After treatment cells were assayed for hematopoietic 
colony  formation  in  rnethylcellutose cultures.  Results  are  expressed  as  the  mean  percent 
control colony formation. CFU-GM, i;  CFU-E, f'q; CFU-MK, I; CFU-GEMM K~. 
fluorescence and flow cytometry as described in  Materials and Methods.  The 
percentage of B43-PAP-labeled BMMNC was 9.1  and 8.1%, respectively. Fig. 5 
shows the effect of 8-h B43-PAP treatment on in vitro progenitor cell recovery 
from these bone marrow samples.  Data are expressed as the mean percent of 
colony  forming  units  (CFU)  recovered per  105  treated  cells  compared  with 
untreated control cultures. Control cultures yielded 159 (range, 150-170) GM, 
118 (range,  105-/31)  E,  12.8 (range, 8-20) pure MK, and  19  (range,  16-21) 
multilineage (GEMM) colonies per  105 BMMNC.  At  10 -8 M  B43-PAP,  mono- 
potent and pluripotent progenitors were only minimally affected. At 4  x  I0 -s 
M,  33%  of  CFU-GM,  48.5%  of  CFU-E,  and  35.5%  of  CFU-GEMM  were 
inhibited. CFU-MK were inhibited only 4%.  As shown in Table VI, B43-PAP 
eliminated up to 99.96%  of common B-lineage ALL progenitor cells at this IT 
concentration. 
Discussion 
In our previous studies, we have evaluated the effects of cyclophosphamide 
congeners  (24),  multiple  antibodies  and  complement  (44),  IT  (13-18),  and 
combination protocols (15,  25,  44) against established leukemia cell lines. Our 
findings revealed a  marked heterogeneity in  the sensitivity of different target 
lymphoblastic  leukemia cell  lines  to  various  reagents.  This  was attributed  to 
considerable differences in cell cycle kinetics, cellular drug metabolism, comple- 
ment sensitivity,  immunological phenotype, and toxin  sensitivity.  Considering 
our  lack  of knowledge about  the  clonogenic blasts  from  ALL  patients  with 
respect  to  the  above  biological  features,  we  concluded  that  the  therapeutic 
potential  of purging  strategies  has  to  be  critically analyzed against  leukemic 
progenitor cells obtained directly from ALL patients. 
In this study, we used a novel colony assay system to evaluate the cytotoxicity 
of B43-PAP, a human B cell-directed IT, against sIg- B-lineage leukemic bone 
marrow progenitor cells freshly obtained from ALL patients.  A  maximum kill UCKUN  ET  AL.  361 
of _>99.96%  of leukemic progenitor cells was achieved after treatment with B43- 
PAP  under  conditions  in  which  <40%  of normal  pluripotent  hematopoietic 
progenitor cells (CFU-GEMM)  were inhibited.  B43-PAP  completely inhibited 
primary blast colony formation in 8 of 10 common B-lineage ALL cases. These 
data establish that the B-lineage-associated surface determinant recognized by 
B43 mAb is expressed on common B-lineage ALL progenitor cells in sufficient 
quantities to allow effective binding and internalization of the IT. Our findings 
further illustrate  that  B-lineage blast  progenitors  are sensitive to  PAP at  the 
ribosomal level. Previous reports from our group have established the immuno- 
logical stability (42) as well as the therapeutic potential (46) of PAP IT in vivo. 
Together with our earlier findings, the results presented here indicate that IT 
containing  PAP  may  be  useful  for  in  vivo  elimination  of residual  leukemic 
progenitor cells from patients with common B-lineage ALL, as well as for ex vivo 
purging of autologous marrow grafts in these patients before autologous BMT. 
The  cytotoxicity of B43-PAP  was  not  limited to  B-lineage progenitor cells 
only, and notably resulted in substantial inhibition of cellular protein synthesis 
in the bulk leukemic bone marrow blast population of all  12 common B-lineage 
ALL  patients.  The  actual  percent  inhibition  of B-lineage  blasts  measured in 
protein synthesis and colony assays slightly differed. However, this is not surpris- 
ing,  since the protein  synthesis assay measures a  short-term (24  h) inhibitory 
effect whereas colony assays evaluate long-term (7 d) inhibition.  Furthermore, 
protein synthesis assays measure the inhibitory effects of IT on the bulk popu- 
lation of leukemic cells, whereas the relatively small  (0.09-2.63%)  clonogenic 
fraction of common B-lineage ALL cell populations  may differ from the bulk 
population  in surface antigen expression, IT entry and degradation, as well as 
PAP sensitivity. 
To our knowledge, B43-PAP  is  the first IT to prove effective against sIg- 
common B-lineage ALL cells. By comparison, ricin A-chain conjugates reactive 
with CALLA, gp26, and B 1 were ineffective in inhibiting the growth of Burkitt's 
lymphoma cell lines (47, 48). Polyclonal rabbit anti-human Ig antibodies linked 
to  ricin  A-chain  were  selectively toxic  against  the  slg  ÷  Daudi  cell  line  (10). 
However, leukemic blasts from common B-lineage ALL patients do not express 
sIg (22, 23, see Table II), and therefore could not be eliminated by anti-human 
Ig IT. Similarly, mAb-toxin conjugates directed against Ia, albeit inhibitory to 
Burkitt's  lymphoma cell  lines (47),  show  little promise for clinical application 
because of crossreactivity with normal monopotent and pluripotent progenitor 
cells (49). 
Surprisingly, the PAP conjugate of T101  mAb (anti-CD5) displayed a moder- 
ate toxicity against common B-lineage ALL cells in the protein synthesis inhibi- 
tion assay. This observation was unexpected, since < ! 0% of B-lineage blasts were 
T ! 01 + as measured by indirect immunofluorescence using FACS. However, it is 
possible that FACS results may not accurately reflect antigen number. Hence, 
the CD5 surface determinant may indeed be present on some B-lineage leukemic 
cells in small but sufficient quantities to allow TI01-PAP binding and internali- 
zation. This T  cell associated antigen is also found on B-lineage chronic lympho- 
cytic leukemia cells bearing sIg (31). >2 ×  106 IT molecules/cell were present at 
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be partially attributed to nonspecific uptake of T101-PAP by pinocytosis. If this 
is true, the variability of T 10 I-PAP toxicity, which ranged from 0 to 32% might 
simply reflect differences in the pinocytotic activity of common B-lineage ALL 
blast populations. Similarly, the differences seen in B43-PAP induced inhibition 
of normal bone marrow progenitor cells can also be explained by differences in 
nonspecific endocytosis of the  IT.  Alternatively,  the  amount  of IT  may be 
comparable, but pinocytosed cells may differ with respect to their PAP sensitivity 
at the ribosomal level. 
The colony assay system described in this paper, as well as the data concerning 
blast colony formation in vitro, differ from those reported by Izaguirre et al. 
(50) in several respects. These authors used a cell culture method that requires 
special incubator chambers with low oxygen tension, extensive depletion of T 
lymphocytes, and presence of irradiated feeder cells. It is noteworthy that these 
investigators obtained no blast colonies in the absence of T  lymphocyte feeders 
and  concluded that,  besides  growth-promoting cytokines, immediate cell-cell 
communications are also required for colony formation. In contrast, using the 
culture technique reported here, we found that neither feeder cells nor special 
low-oxygen incubator chambers are required for reproducible growth of freshly 
obtained leukemic B-lineage bone marrow blasts.  We are currently studying the 
correlations between various clinical parameters and colony formation in  our 
assay system. Notably, in 21 of 30 common B-lineage ALL bone marrow samples 
evaluated in experiments thus far, successful cultures with blast colony formation 
were obtained in the absence of T  lymphocyte feeders (Uckun, Kersey, Haag, 
Gajl-Peczalska, Heerema, Arthur, LeBien, Vallera; manuscript in preparation). 
Hence, our experience with highly enriched bone marrow blast populations does 
not support the contention that immediate cell-cell interactions between leukemic 
B-lineage blasts and normal T  lymphocytes are essential for blast colony forma- 
tion. 
In agreement with the findings of Izaguirre et al.  (50),  we found that blast 
colony formation  requires  the presence  of PHA-LCM.  However,  the  use  of 
human plasma and FCS is also essential for B-lineage blast colony formation in 
our assay system. Only the combined use of these three supplements reproducibly 
supported the in vitro proliferation of leukemic bone marrow blasts from patients 
with  common  B-lineage  ALL.  The  use  of human  plasma  has  the  additional 
advantage that it increases the viscous support in methylcellulose cultures. This 
decreases cell migration in  marrow cultures and  increases the likelihood that 
blast  colonies are derived from single leukemic progenitor cells.  Blast  colony 
formation was linear with respect to numbers of cultured cells between 103 and 
105 leukemic blasts per milliliter. This linear pattern of colony growth is consist- 
ent with near to optimal culture conditions, and also suggests a single cell origin 
of B-lineage blast colonies. 
The primary plating efficiency of blast progenitor cells varied between 0.09 
and  2.63%.  This  variation  might  represent  fluctuations  in  blast  progenitor 
physiology occuring at random during the course of leukemia. Alternatively, the 
primary plating efficiency might be a stable blast progenitor property unique to 
each case. If the latter is true, our findings indicate a marked heterogeneity in 
proliferative potential among the common B-lineage ALL blast populations.  In UCKUN  ET  AL.  363 
each ALL case with  successful cultures, day 7  colonies displayed a  significant 
variation in cell number. This finding suggests that the clonogenic fraction of 
the leukemic blast population in each patient contains cells that are heterogenous 
with respect to their cell cycle kinetics. 
The capacity of blast progenitors to undergo self-renewal results in the main- 
tainence of cycling blast populations.  The evaluation of the secondary plating 
efficiency yields valuable information about the self-renewal property of blast 
progenitor cells (51).  Therefore, we attempted to determine the self-renewal 
ability of leukemic B-lineage progenitor cells in replating experiments, and found 
that the secondary plating efficiencies did not exceed 7.12%. The majority of B- 
lineage lymphoblasts pooled from primary day 7 colonies and recultured did not 
proliferate and form secondary colonies. Thus, only a very small fraction of the 
progeny of blast progenitor cells displayed progenitor cell characteristics. These 
data  are  consonant  with  previous  findings  obtained  by  Izaguirre  et  al.  (50). 
Similar  findings  were  reported  by  Buick  et  ai.  (52),  who evaluated  the  self- 
renewal property of myeloid-lineage blast progenitor cells in replating experi- 
ments. 
Morphological, cytochemicai, and immunological analyses of cells pooled from 
primary day 7 colonies provided the evidence that they are B-lineage lympho- 
blasts. Izaguirre et al. (50) reported that cells within blast colonies have the same 
immunological phenotype as the cells in marrow or blood of the patients from 
whom the colonies were propagated.  In contrast, in 7 of 10 common B-lineage 
ALL cases with successful marrow cultures presented in this paper, the immu- 
nological  phenotype  of  day  7  colony  blasts  differed  significantly  from  the 
evaluation of the bulk bone marrow blast population before culture. In 3 of 10 
cases,  the colony blasts  did not express CD10/CALLA.  In one of these three 
cases, colony blasts were recultured to evaluate their self-renewal ability. Cells har- 
vested  from  secondary blast  colonies were found  to  be also  CD10/CALLA- 
negative.  Our  findings  may be  interpreted as  an  indication  of the  existence 
of CD10/CALLA-negative  leukemic progenitor cells in  the bone  marrow of 
patients  with  common  B-lineage  ALL.  This  hypothesis  is  supported  by  the 
phenotypic shifts observed during the clinical course of common B-lineage ALL. 
Greaves et al. (53) reported that, in relapse ALL, CD10/CALLA may be lost as 
compared with  the phenotype at diagnosis.  Such alterations in  immunological 
phenotype were also observed in a  more recent clinical study at our institution 
(19).  Since ALL blast  populations are most likely subject to selective pressure 
and clonal evolution, the phenotypic shifts in  common B-lineage ALL during 
leukemia progression or relapse may be due to a  change in the balance of the 
determining influences with time, or after chemotherapy. In the aforementioned 
group of three ALL cases with CALLA-negative colony blasts, the expression of 
CD24 determinant defined by BA-!  mAb was also significantly greater on the 
preculture blast population  than on  the cultured blasts.  Although evidence of 
monoclonality for the colony blasts would have been highly desirable, we were 
unable to use chromosome abnormalities or rearrangements of Ig genes as clonal 
markers because of the limited number of cells obtained from day 7 B-lineage 
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marker analyses, we did not have sufficient colony cells left to evaluate their 
clonality. 
Unlike CD10/CALLA and CD24,  the CD9  surface determinant recognized 
by BA-2, as well as the antigen recognized by B43 mAb were strongly expressed 
in all cases by the vast majority of cultured blasts. The conserved expression of 
these  B-lineage  markers might be  taken  to  indicate  that  they may represent 
surface receptors functionally involved in cell-cell interactions, proliferation, and 
clonogenic growth control of B-lineage ALL blast populations. 
In conclusion, we have described a new assay system that allows reproducible 
proliferation and colony formation of freshly cultured bone marrow blasts from 
patients with common B-lineage ALL. Experimental data produced in this model 
system of leukemic B-lineage progenitor cells will likely provide information of 
value in  understanding the underlying biological events that influence growth 
progression and  control of leukemic hematopoietic stem cells  in  common B- 
lineage ALL. A  major finding of clinical significance presented in this paper is 
that B-lineage leukemic progenitor cells can be effectively eradicated by an IT 
containing PAP. These experiments provide a paradigm for the critical evalua- 
tion of the therapeutic potential of an antileukemic treatment strategy in common 
B-lineage ALL. 
Summary 
We report a novel colony assay for B-lineage progenitor cells in acute lympho- 
blastic  leukemia  (ALL).  The  primary  plating  efficiency of blast  progenitors 
freshly obtained from common B-lineage ALL patients varied between 0.09 and 
2.63%.  Morphological, cytochemical, and immunological analyses of cells from 
day  7  colonies  provided  the  evidence  that  they are  B-lineage  lymphoblasts. 
Immunological marker analyses of cultured blasts using BA-2 (anti-CD9), BA-3 
(anti-CD10),  BA-1  (anti-CD24),  and  B43  mAb have allowed us to define two 
distinct immunological groups. The first group had BA-2  +, BA-3 +, BA-1 +, B43 + 
marker profiles, consistent with the phenotype of uncultured bone marrow blasts. 
The second group differed in that the cells in the blast colonies were BA-3 (anti- 
CD10)-negative, although many of the cells in the bulk population were BA-3 + 
before  culture.  Blasts  from  both  groups  were  able  to  proliferate  and  form 
secondary colonies when recuitured. 
A pan-B immunotoxin was synthesized by linking B43, a human B cell-specific 
mAb,  to pokeweed antiviral protein (PAP). This  study showed that  B43-PAP 
can effectively eradicate leukemic progenitor cells freshly obtained from patients 
with common B-lineage ALL. B43-PAP eliminated >99.96% of blast progenitors 
under  conditions  in  which  only  minimal  inhibition  of normal  bone  marrow 
progenitor cells (CFU-GM, CFU-E, CFU-MK, CFU-GEMM) was observed. Our 
results establish that the surface determinant recognized by B43 is expressed on 
B-lineage progenitor cells in  ALL, and that these cells are sensitive to PAP at 
the ribosomal level. To our knowledge, B43-PAP is the first IT to prove effective 
against common B-lineage ALL cells. 
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